logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

Mar 25, 2024•over 1 year ago

Acquiring Company

Nuvation Bio

Acquired Company

AnHeart Therapeutics

New YorkNew YorkBiopharmaTherapeuticsBiotechnologyHealth CareBiopharmaTherapeuticsPharmaceuticalBiotechnologyHealth Care

Description

Nuvation Bio Inc. (NYSE: NUVB) and AnHeart Therapeutics Ltd. have entered into a definitive agreement for Nuvation Bio to acquire AnHeart in an all-stock transaction. This acquisition will strengthen Nuvation Bio's position as a late-stage global oncology company with a focus on delivering novel cancer therapies.

Company Information

Company

Nuvation Bio

Location

New York, New York, United States

About

Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco. For more information, please visit www.nuvationbio.com.

Related People

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed